Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program €25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D program Institutional-grade capital: Potential long-term, attractively structured financing from the EU's premier development bank R&D acceleration: Strengthens and expands the Company's development pipeline across its portfolio Value creation catalyst: Landmark funding opportunity supporting long-term innovation and growth CHICAGO, IL / ACCESS Newswire / May 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development (R&D) financing program with the European Investment Bank (EIB), the financing arm of the European Union and one of the world's largest multilateral lenders. In connection with this initiative, Cana Laboratories has entered into an advisory agreement with the EIB to support the Company's progress under the EIB-backed financing program.